NCT04407078View on ClinicalTrials.gov

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

January 6, 2021

Study Completion Date

January 6, 2021

Conditions
Gallbladder Diseases
Interventions
DRUG

Sugammadex Injectable Product

Sugammadex of 2 mg/kg is injected.

DRUG

Neostigmine Injectable Product

Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Trial Locations (1)

16499

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon

All Listed Sponsors
lead

Ajou University School of Medicine

OTHER

NCT04407078 - Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female | Biotech Hunter | Biotech Hunter